Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miltefosine vs Standard Care for Cutaneous Leishmaniasis in Brazil
NCT00600548Phase 2Completed
- Sponsor
- Hospital Universitário Professor Edgard Santos
- Start
- Jul 2007
- Primary completion
- Mar 2009
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of miltefosine in cutaneous leishmaniasis (CL) (4 arms), sponsored by Hospital Universitário Professor Edgard Santos. Primary endpoint: Cure rate or complete cicatrization of the ulcer at 6 months. Started Jul 2007; status: completed.
02
Drugs
miltefosine
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on NCT00600548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00600548.